Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
about
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapyInsights into CYP2B6-mediated drug-drug interactionsIsoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalitiesPopulation pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Differences in Methadone Metabolism by CYP2B6 VariantsMethadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismEffects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexPharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceMethadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis.Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects.
P2860
Q26852535-49990F2D-39A8-4179-A308-E0F83BF2DA9BQ28078857-53FC5A07-DAA0-4DE3-93BF-464053141CAEQ33798516-0F293397-521A-47BE-A544-A0B97AF355C0Q33821729-87A43B58-EB14-4FA5-BC3C-166C19E1E072Q35106387-3F3D5C4F-B4ED-45DD-B39F-3134491FD7FDQ35547723-675EF13B-32DF-42B5-8F6A-6CC050B56B69Q35745266-44C8CFB4-581F-4A3D-AF63-5410E2CD59BFQ36342286-2F7B93CB-3AA7-481C-B37D-BD3940C4A8E6Q36562516-C7D3339C-EDAF-4D98-9C69-EE067DD981A7Q36657589-87E6D400-3BFE-42C6-83E2-51AD0BC5409BQ36717150-6132A05D-E1FE-45FB-B010-8A16878B6B71Q36820603-8F47E9D0-7319-48A7-8336-70AAC0400A11Q37126489-4C45AEF8-623A-4ADF-8DB9-469388A124DDQ37325589-320571C3-1767-489E-9EF7-36E388CA3572Q37358704-09D1955E-65BC-43CB-A644-643C658D9FAEQ37604428-9691410D-1957-47C4-8496-9FCB25EAB641Q55262171-F9B7EFDA-9A8E-4C6A-B514-E35511AE31E5
P2860
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@ast
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@en
type
label
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@ast
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@en
prefLabel
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@ast
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@en
P2093
P2860
P356
P1476
Effects of the CYP2B6*6 allele ...... her CYP2B6 substrates in vivo.
@en
P2093
Evan T Ogburn
Yingying Guo
P2860
P304
P356
10.1124/DMD.111.042416
P577
2012-01-09T00:00:00Z